Spider minor ampullate silk protein nanoparticles: an effective protein delivery system capable of enhancing systemic immune responses

Abstract

Spider silk proteins (spidroins) are particularly attractive due to their excellent biocompatibility. Spider can produce up to seven different types of spidroins, each with unique properties and functions. Spider minor ampullate silk protein (MiSp) might be particularly interesting for biomedical applications, as the constituent silk is mechanically strong and does not super-contract in water, attributed to its amino acid composition. In this study, we evaluate the potential of recombinant nanoparticles derived from Araneus ventricosus MiSp as a protein delivery carrier. The MiSp-based nanoparticles were able to serve as an effective delivery system, achieving nearly 100% efficiency in loading the model protein lysozyme, and displayed a sustained release profile at physiological pH. These nanoparticles could significantly improve the delivery efficacy of the model proteins through different administration routes. Furthermore, nanoparticles loaded with model protein antigen lysozyme after subcutaneous or intramuscular administration could enhance antigen-specific immune responses in mouse models, through a mechanism involving antigen-depot effects at the injection site, long-term antigen persistence, and efficient uptake by dendritic cells as well as internalization by lymph nodes. These findings highlight the transnational potential of MiSp-based nanoparticle system for protein drug and vaccine delivery.

Keywords

immune response / nanoparticles / protein controlled release / spidroin

References

1	T Lefèvre, M Auger. Spider silk as a blueprint for greener materials: a review. Int Mater Rev. 2016;61(2):127-153.
2	M Ramezaniaghdam, ND Nahdi, R Reski. Recombinant spider silk: promises and bottlenecks. Front Bioeng Biotechnol. 2022;10:835637.
3	PL Babb, NF Lahens, SM Correa-Garhwal, et al. The Nephila clavipes genome highlights the diversity of spider silk genes and their complex expression. Nat Genet. 2017;49(6):895-903.
4	A Rising, J Johansson. Toward spinning artificial spider silk. Nat Chem Biol. 2015;11(5):309-315.
5	C Allmeling, A Jokuszies, K Reimers, et al. Spider silk fibres in artificial nerve constructs promote peripheral nerve regeneration. Cell Prolif. 2008;41(3):408-420.
6	F Vollrath, P Barth, A Basedow, W Engstr?m, H List. Local tolerance to spider silks and protein polymers in vivo. In vivo (Athens, Greece). 2002;16(4):229-234.
7	MM Moisenovich, OL Pustovalova, AY Arhipova, et al. In vitro and in vivo biocompatibility studies of a recombinant analogue of spidroin 1 scaffolds. J Biomed Mater Res Part A. 2011;96(1):125-131.
8	C Fredriksson, M Hedhammar, R Feinstein, et al. Tissue response to subcutaneously implanted recombinant spider silk: an in vivo study. Materials. 2009;2(4):1908-1922.
9	K Spiess, A Lammel, T Scheibel. Recombinant spider silk proteins for applications in biomaterials. Macromol Biosci. 2010;10(9):998-1007.
10	M Hofer, G Winter, J Myschik. Recombinant spider silk particles for controlled delivery of protein drugs. Biomaterials. 2012;33(5):1554-1562.
11	M Humenik, K Pawar, T Scheibel, Nanostructured, self-assembled spider silk materials for biomedical applications. Adv Exp Med Biol. 2019;1174:187-221.
12	M Lucke, I Mottas, T Herbst, et al. Engineered hybrid spider silk particles as delivery system for peptide vaccines. Biomaterials. 2018;172:105-115.
13	K Schacht, T Scheibel. Processing of recombinant spider silk proteins into tailor-made materials for biomaterials applications. Curr Opin Biotechnol. 2014;29:62-69.
14	S Salehi, K Koeck, T Scheibel. Spider silk for tissue engineering applications. Molecules (Basel, Switzerland). 2020;25(3).
15	UK Slotta, S Rammensee, S Gorb, T Scheibel. An engineered spider silk protein forms microspheres. Angew Chem (International ed in English). 2008;47(24):4592-4594.
16	A Lammel, M Schwab, U Slotta, G Winter, T Scheibel. Processing conditions for the formation of spider silk microspheres. ChemSusChem. 2008;1(5):413-416.
17	A Lammel, M Schwab, M Hofer, G Winter, T Scheibel. Recombinant spider silk particles as drug delivery vehicles. Biomaterials. 2011;32(8):2233-2240.
18	K Jastrzebska, A Florczak, K Kucharczyk, et al. Delivery of chemotherapeutics using spheres made of bioengineered spider silks derived from MaSp1 and MaSp2 proteins. Nanomedicine (London, England). 2018;13(4):439-454.
19	G Chen, X Liu, Y Zhang, et al. Full-length minor ampullate spidroin gene sequence. PLoS one. 2012;7(12):e52293.
20	X Qi, Y Wang, H Yu, et al. Spider silk protein forms amyloid-like nanofibrils through a non-nucleation-dependent polymerization mechanism. Small (Weinheim an der Bergstrasse, Germany). 2023:e2304031.
21	AN Tsoras, JA Champion. Protein and peptide biomaterials for engineered subunit vaccines and immunotherapeutic applications. Annu Rev Chem Biomol Eng. 2019;10:337-359.
22	F Mottaghitalab, M Farokhi, MA Shokrgozar, F Atyabi, H Hosseinkhani. Silk fibroin nanoparticle as a novel drug delivery system. J Control Release. 2015;206:161-176.
23	A Stano, C Nembrini, MA Swartz, JA Hubbell, E Simeoni. Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization. Vaccine. 2012;30(52):7541-7546.
24	S Rammensee, U Slotta, T Scheibel, AR Bausch. Assembly mechanism of recombinant spider silk proteins. Proc Natl Acad Sci USA. 2008;105(18):6590-6595.
25	K Jastrzebska, E Felcyn, M Kozak, et al. The method of purifying bioengineered spider silk determines the silk sphere properties. Sci Rep. 2016;6:28106.
26	M Otikovs, G Chen, K Nordling, et al. Diversified structural basis of a conserved molecular mechanism for pH-dependent dimerization in spider silk N-terminal domains. Chembiochem. 2015;16(12):1720-1724.
27	SE Howe, DJ Lickteig, KN Plunkett, JS Ryerse, V Konjufca. The uptake of soluble and particulate antigens by epithelial cells in the mouse small intestine. PLoS One. 2014;9(1):e86656.
28	R Kuolee, W Chen. M cell-targeted delivery of vaccines and therapeutics. Expert Opin Drug Deliv. 2008;5(6):693-702.
29	S Rashki, K Asgarpour, H Tarrahimofrad, et al. Chitosan-based nanoparticles against bacterial infections. Carbohydr Polym. 2021;251:117108.
30	A Hill, M Beitelshees, BA Pfeifer. Vaccine delivery and immune response basics. Methods Mol Biol. 2021;2183:1-8.
31	FZ Firdaus, M Skwarczynski, I Toth. Developments in vaccine adjuvants. Methods Mol Biol (Clifton, NJ). 2022;2412:145-178.
32	GJ Russell-Jones. Oral vaccine delivery. J Control Release. 2000;65(1-2):49-54.
33	MA Tomeh, R Hadianamrei, X Zhao. Silk fibroin as a functional biomaterial for drug and gene delivery. Pharmaceutics. 2019;11(10).
34	AP Kiseleva, PV Krivoshapkin, EF Krivoshapkina. Recent advances in development of functional spider silk-based hybrid materials. Front Chem. 2020;8:554.
35	MB Elsner, HM Herold, S Müller-Herrmann, H Bargel, T Scheibel. Enhanced cellular uptake of engineered spider silk particles. Biomater Sci. 2015;3(3):543-551.
36	N Hoshyar, S Gray, H Han, G Bao. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (London, England). 2016;11(6):673-692.
37	ST Reddy, A Rehor, HG Schmoekel, JA Hubbell, MA Swartz. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Control Release. 2006;112(1):26-34.
38	YM Park, SJ Lee, YS Kim, et al. Nanoparticle-based vaccine delivery for cancer immunotherapy. Immune Netw. 2013;13(5):177-183.
39	V Saini, V Jain, MS Sudheesh, KS Jaganathan, PK Murthy, DV Kohli. Comparison of humoral and cell-mediated immune responses to cationic PLGA microspheres containing recombinant hepatitis B antigen. Int J Pharm. 2011;408(1-2):50-57.
40	N Asadi, S Davaran, Y Panahi, et al. Application of nanostructured drug delivery systems in immunotherapy of cancer: a review. Artif Cells Nanomed Biotechnol. 2017;45(1):18-23.
41	D Peckus, A Tamulevi?ien?, K Mougin, et al. Shape influence on the ultrafast plasmonic properties of gold nanoparticles. Optics Express. 2022;30(15):27730-27745.
42	W Zhang, L Wang, Y Liu, et al. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation. Biomaterials. 2014;35(23):6086-6097.
43	MP Neubauer, C Blüm, E Agostini, J Engert, T Scheibel, A Fery. Micromechanical characterization of spider silk particles. Biomater Sci. 2013;1(11):1160-1165.
44	X Zhong, Y Zhang, L Tan, et al. An aluminum adjuvant-integrated nano-MOF as antigen delivery system to induce strong humoral and cellular immune responses. J Control Release. 2019;300:81-92.
45	OP Joffre, E Segura, A Savina, S Amigorena. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557-569.
46	T Ahrends, A Spanjaard, B Pilzecker, et al. CD4(+) T cell help confers a cytotoxic T cell effector program including coinhibitory receptor downregulation and increased tissue invasiveness. Immunity. 2017;47(5):848-861.
47	X Zhong, G Du, X Wang, et al. Nanovaccines mediated subcutis-to-intestine cascade for improved protection against intestinal infections. Small (Weinheim an der Bergstrasse, Germany). 2022;18(1):e2105530.
48	SL Demento, W Cui, JM Criscione, et al. Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. Biomaterials. 2012;33(19):4957-4964.
49	DA Blair, DL Turner, TO Bose, et al. Duration of antigen availability influences the expansion and memory differentiation of T cells. J Immunol (Baltimore, Md: 1950). 2011;187(5):2310-2321.
50	X Qi, H Wang, K Wang, et al. Spiders use structural conversion of globular amyloidogenic domains to make strong silk fibers. Adv Funct Mater. 2024.
51	H Cai, G Chen, H Yu, Y Tang, S Xiong, X Qi. One-step heating strategy for efficient solubilization of recombinant spider silk protein from inclusion bodies. BMC Biotechnol. 2020;20(1):37.
52	X Qi, Y Sun, S Xiong. A single freeze-thawing cycle for highly efficient solubilization of inclusion body proteins and its refolding into bioactive form. Microb Cell Factor. 2015;14:24.
53	X Qi, Q Lu, J Hu, S Xiong. Spontaneous C-cleavage of a truncated intein as fusion tag to produce tag-free VP1 inclusion body nanoparticle vaccine against CVB3-induced viral myocarditis by the oral route. Microb Cell Factor. 2019;18(1):66.